ទំព័រដើម › មហារីកពោះវៀនធំ និងទ្វារមាស › តិចាស › San Antonio
ការសាកល្បងគ្លីនិកសម្រាប់ មហារីកពោះវៀនធំ និងទ្វារមាស នៅក្នុង San Antonio, TX
ការសិក្សាចំនួន 46 សម្រាប់ មហារីកពោះវៀនធំ និងទ្វារមាស កំពុងរកអ្នកចូលរួមនៅតាមទីតាំងក្នុង និងជុំវិញ San Antonio (ក្នុងចម្ងាយប្រហែល 30 ម៉ាយ)។ បើកការសិក្សាមួយដើម្បីមើលថាតើនរណាអាចចូលរួម និងរបៀបទំនាក់ទំនងទៅកាន់ក្រុមការងារសិក្សា។
អត្ថបទសិក្សាផ្លូវការ (អង់គ្លេស)
កំពុងរកអ្នកចូលរួមសម្រាប់ការសិក្សាមួយនៅទីនេះ? លេចធ្លោនៅផ្នែកខាងលើនៃទំព័រនេះ — $99 សម្រាប់ 30 ថ្ងៃ →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
កំពុងជ្រើសរើសការសិក្សាសង្កេតស្វាគមន៍អ្នកស្ម័គ្រចិត្តដែលមានសុខភាពល្អ
- Audie L Murphy VA Hospital, San Antonio
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- University of Texas San Antonio (UTSA), San Antonio
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
កំពុងជ្រើសរើសដំណាក់កាល 3
- Texas Oncology - San Antonio, San Antonio
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
កំពុងជ្រើសរើសដំណាក់កាល 3
- Texas Oncology - San Antonio, San Antonio
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- START San Antonio, San Antonio
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2/3
- Texas Oncology - San Antonio, San Antonio
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology San Antonio, San Antonio
- START Texas, San Antonio
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT, San Antonio
- START - San Antonio, San Antonio
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- START San Antonio, San Antonio
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
កំពុងជ្រើសរើសដំណាក់កាល 3
- Texas Oncology- San Antonio, San Antonio
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
កំពុងជ្រើសរើសដំណាក់កាល 2
- Mays Cancer Center at University of Texas Health at San Antonio, San Antonio
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT San Antonio, San Antonio
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- South Texas Accelerated Research Therapeutics (START), San Antonio
FOG-001 in Locally Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- UT Health Mays Cancer Center, San Antonio
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Clinical Trial Site, San Antonio
IDOV-Immune for Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- South Texas Accelerated Research Therapeutics, San Antonio
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- GSK Investigational Site, San Antonio
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology, San Antonio
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Texas Oncology - San Antonio, San Antonio
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- Next Oncology, San Antonio
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- START San Antonio, San Antonio
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- START San Antonio, LLC., San Antonio
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- New Experimental Therapeutics of San Antonio LLC, San Antonio
- START - South Texas Accelerated Research Therapeutics, LLC, San Antonio
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Next Oncology-Oncology, San Antonio
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Texas LLC - San Antonio, San Antonio
- START San Antonio, LLC, San Antonio
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Texas LLC - San Antonio, San Antonio
- Start San Antonio, LLC, San Antonio
CT-95 in Advanced Cancers Associated With Mesothelin Expression
កំពុងជ្រើសរើសដំណាក់កាល 1
- Context Investigational Site, San Antonio
- Context Investigational Site, San Antonio
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
កំពុងជ្រើសរើសដំណាក់កាល 1
- Research Site #2, San Antonio
- Research Site, San Antonio
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- START, San Antonio
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology, San Antonio
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Next Oncology, San Antonio
A Study of MGC028 in Participants With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- South Texas Accelerated Research Therapeutics (START) San Antonio, San Antonio
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- NEXT Oncology, San Antonio
A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1
- NEXT Oncology, San Antonio
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- South Texas Accelerated Research Therapeutics, LLC, San Antonio
- UT Health San Antonio, San Antonio
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- START San Antonio, San Antonio
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- START San Antonio, San Antonio
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
កំពុងជ្រើសរើសដំណាក់កាល 1/2
- Next Oncology, San Antonio, San Antonio
ការសាកល្បងសម្រាប់ មហារីកពោះវៀនធំ និងទ្វារមាស នៅក្នុងទីក្រុងផ្សេងទៀត
- Houston, TXការសិក្សា 102
- New York City, NYការសិក្សា 78
- Nashville, TNការសិក្សា 69
- Boston, MAការសិក្សា 63
- Los Angeles, CAការសិក្សា 59
- Arlington, VAការសិក្សា 52
- St. Louis, MOការសិក្សា 50
- Philadelphia, PAការសិក្សា 44
- Grand Rapids, MIការសិក្សា 40
- Baldwin Park, CAការសិក្សា 37
- Chicago, ILការសិក្សា 34
- Tampa, FLការសិក្សា 34
ការសិក្សាផ្សេងទៀតនៅក្នុង San Antonio
- Non-Small Cell Lung Cancerការសិក្សា 59
- មហារីកទ្រូងការសិក្សា 47
- មហារីកដែលរីករាលដាលការសិក្សា 44
- មហារីក (គ្រប់ប្រភេទ)ការសិក្សា 41
- ជំងឺធាត់ការសិក្សា 40
- ជំងឺទឹកនោមផ្អែមប្រភេទ ២ការសិក្សា 37
- ទម្ងន់លើសការសិក្សា 34
- មហារីកស៊ុតការសិក្សា 31
- មហារីកតំបក់ការសិក្សា 31
- មហារីកតូចការសិក្សា 28
- មហារីកស្រទាប់ស្បែកស្តីការសិក្សា 27
- មហារីកសួតការសិក្សា 26
ពី ClinicalTrials.gov, ទិន្នន័យទទួលបាននៅថ្ងៃ 6 តុលា 2026។ ការសិក្នានីមួយៗកំណត់លក្ខខណ្ឌលក្ខណៈសម្បត្តិរបស់ខ្លួន; ក្រុមការងារសិក្សាកំណត់ថាតើនរណាអាចចូលរួម។